tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Matthew Luchini, 49 are a HOLD (38.89%), 77 are a BUY (61.11%).
Analyst Matthew Luchini, currently employed at BMO, carries an average stock price target met ratio of 44.27% that have a potential upside of 22.62% achieved within 180 days.
Matthew Luchini’s has documented 272 price targets and ratings displayed on 26 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on REPL, Replimune Group at 18-Mar-2022.
Analyst best performing recommendations are on BLUE (BLUEBIRD BIO).
The best stock recommendation documented was for BLUE (BLUEBIRD BIO) at 6/6/2017. The price target of $1398.96 was fulfilled within 1 day with a profit of $127.57 (10.03%) receiving and performance score of 100.34.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 25-Oct-2022
3 years 4 months 26 days ago
(25-Oct-2022)
1/10 (10%)
$13.99 (348.88%)
848
Hold Since 25-Oct-2022
$0.4
$0.01 (2.56%)
3 years 4 months 26 days ago
(25-Oct-2022)
1/1 (100%)
$0.01 (2.56%)
2
Hold
3 years 4 months 27 days ago
(24-Oct-2022)
0/1 (0%)
$7.55 (308.16%)
Hold Since 06-May-2020
3 years 4 months 27 days ago
(24-Oct-2022)
0/2 (0%)
$2.73 (29.45%)
Hold Since 29-Sep-2022
$11
3 years 5 months 22 days ago
(29-Sep-2022)
0/2 (0%)
$6.72 (157.01%)
What Year was the first public recommendation made by Matthew Luchini?
